Axa
CDLX icon

Axa’s Cardlytics CDLX Stock Holding History

Axa’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,710
Closed -$947K – 1238
2020
Q1 		$947K Buy
2,710
+2,260
+502% +$1.6M ﹤0.01% 864
2019
Q4 		$283K Buy
+450
New +$220K ﹤0.01% 1082

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Axa's CDLX Position: Q2 2020 in Review

Axa sold out of Cardlytics (CDLX) in Q2 2020, closing a stake of 2,710 shares — an estimated $947K sold.

Axa first reported a position in CDLX in Q4 2019 and held it in 2 quarters. The position peaked at $947K in Q1 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q2 2020.

  • Axa reported no remaining Cardlytics position as of Q2 2020 after selling out during the quarter.
  • Axa sold 2,710 Cardlytics shares in Q2 2020, an estimated $947K.
  • Axa first reported a position in Cardlytics in Q4 2019 and held it in 2 quarters.
  • Axa's Cardlytics position peaked at $947K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Cardlytics as of Q2 2020.

Based on Axa's 13F filing for Q2 2020, filed 14 Aug 2020.